Several studies have investigated the impact of neutropenic diets on infection risk and mortality among cancer patients. A systematic review and meta-analysis found that there was no significant ...

X4 expects its efforts will decrease annual spending by $30-35 million and believes it will have sufficient funds to support operations into the first half of 2026. Workforce reductions are expected ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.

Nearly one year after winning an FDA drug approval to treat an ultra-rare disease, X4 Pharmaceuticals is making layoffs that ...

Objectives To assess the incidence of neutropenia, febrile neutropenia, documented infection with neutropenia and fever associated with early-stage breast cancer (BC) in a real-life setting. Methods A ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

X4 Pharmaceuticals, Inc.’s XFOR share price has dipped by 10.83%, which has investors questioning if this is right time to ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...